CIDR 1.38 g Vaginal Delivery System for Cattle

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Progesterone

Available from:

Zoetis UK Limited

ATC code:

QG03DA04

INN (International Name):

Progesterone

Pharmaceutical form:

Vaginal delivery system

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cattle

Therapeutic area:

Hormone sex

Authorization status:

Authorized

Authorization date:

2008-02-20

Summary of Product characteristics

Revised: November 2023
AN: 02649/2022
Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CIDR 1.38 g vaginal delivery system for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
EACH DEVICE CONTAINS
ACTIVE SUBSTANCE:
Progesterone 1.38 g
EXCIPIENTS:
QUALITATIVE COMPOSITION OF
EXCIPIENTS AND OTHER CONSTITUENTS
Silicone elastomer
Nylon spine
Polyester Tail
A “T” shaped device consists of progesterone impregnated silicone
elastomer skin
moulded over an inert nylon spine.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cattle (cows and heifers).
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
For the control of the oestrous cycle in cycling cows and heifers,
including:
Synchronisation of oestrus in groups of animals including fixed time
artificial
insemination (FTAI) programmes.
Synchronisation of donor and recipient animals for embryo transfer.
To be used in combination with prostaglandin F2

or analogue.
Use as recommended, normally results in oestrus 48-96 hours after
device removal
with the majority of animals showing oestrus within 48-72 hours.
For induction and synchronisation of oestrus in Fixed Time Artificial
Insemination
(FTAI) protocols:
In cycling cows and heifers. To be used in combination with
prostaglandin F2

(PGF2α) or analogue.
Revised: November 2023
AN: 02649/2022
Page 2 of 8
In cycling and non-cycling cows and heifers. To be used in combination
with
Gonadotrophin releasing hormone (GnRH) or analogue and PGF2α or
analogue.
In non-cycling cattle. To be used in combination with PGF2α or
analogue and equine
chorionic gonadotrophin (eCG).
3.3
CONTRAINDICATIONS
Do not use in cows or heifers, with abnormal or immature genital
tracts, or with
genital infections.
Do not use in pregnant cattle.
Do not use within the first 35 days after calving.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
3.4
SPECIAL WARNINGS
The progesterone treatment alone, according to dosage regimen
proposed, is not
sufficient to induce oest